Lanean...
Biomarkers for Programmed Death‐1 Inhibition in Prostate Cancer
Prostate cancer is the second leading cause of cancer death in American men. Despite the common nature of this disease, there is a poor understanding of biomarkers that predict responsiveness to immunotherapeutic agents such as the programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) inhi...
Gorde:
| Argitaratua izan da: | Oncologist |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Inc.
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6459247/ https://ncbi.nlm.nih.gov/pubmed/30541755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0546 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|